Respiratory Virus Infection Drugs Market - Global Industry Analysis

Respiratory Virus Infection Drugs Market - By Drug Type (Antibiotics, Nasal Decongestants, Non-Steroidal Anti-Inflammatory Drugs, and Cough Suppressants), By Infection Type (Respiratory Syncytial Virus Infection, Adenovirus Infection, Influenza Virus Infection, Para influenza Virus Infection, and Rhinovirus Infection), By Distribution Channel(Hospital Pharmacies, Clinics, Retail Pharmacies, and Drug Stores ), By Route of Administration (Oral and Parenteral), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2028

Published Date: 11-Aug-2021 Category: Pharmaceutical Report Format : PDF Pages: 140 Report Code: ZMR-6584 Status : Published

The global Respiratory Virus Infection Drugs market accrued earnings worth approximately 40.12 (USD Billion) in 2020 and is predicted to gain revenue of about 57.23(USD Billion) by 2028, is set to record a CAGR of nearly 7.5% over the period from 2021 to 2028.

Description

The global Respiratory Virus Infection Drugs market accrued earnings worth approximately 40.12 (USD Billion) in 2020 and is predicted to gain revenue of about 57.23(USD Billion) by 2028, is set to record a CAGR of nearly 7.5% over the period from 2021 to 2028. The report offers assessment and analysis of the Respiratory Virus Infection Drugs market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Billion).

Report Scope :

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Respiratory Virus Infection Drugs Market: Overview

Respiratory viruses such as influenza, coronavirus, Para influenza, rhinovirus, respiratory syncytial virus, and human metapneumovirus are the most common causes of respiratory virus infections in immuno-compromised persons. Moreover, early diagnosis & treating of these infections through drugs can prove to be effective & beneficial for immuno-compromised patients affected due to respiratory virus infections since viral replication & invasive infection can prove to be fatal. Since past few years newly emerging viral respiratory pathogens such as avian influenza, pandemic influenza, SARS-CoV, and MERS-CoV have been constantly posing challenge to private as well as public healthcare systems. Hence, there is a growing necessity for developing cost-efficient anti-viral agents & drugs. Recently, antiviral drugs are being developed by virologists & pharmaceutical firms for targeting viral entry, virus replication, and virus release for inhibiting proliferation & blocking growth & spread of virus in human body.

According to NIH researchers, Amantadine and Rimantadine medicines/pharmacokinetics are used for inhibiting replication of influenza A virus through interfering with viral M2 protein activity. Moreover, both Amantadine and Rimantadine have proved to be effective in low proportions against influenza B virus. Reportedly, both these drugs are administered in oral form as tablets or in syrup form at 5mg per kg of body mass for children. They are administered nearly up to 200 mg per day for adults. As per clinical trials, both Amantadine and Rimantadine have proved effective in preventing influenza in over 60% of subjects. For the record Zanamivir and Oseltamivir available for oral administration in powdered, capsule, and liquid form has also helped in preventing influenza infections in over 65% of subjects.

Respiratory Virus Infection Drugs Market: Growth Drivers

Massive use of artificial intelligence and machine learning in drug discovery is projected to favorably influence growth of respiratory virus infection drugs market. Humungous use of combination therapy is projected to boost rate of success of treating respiratory virus infection through anti-viral drugs. This, in turn, will facilitate elevation of respiratory virus infection drugs market size in upcoming years. Apart from this, effective drug delivery through nanotechnology is projected to provide new growth prospects for respiratory virus infection drugs market in near future. In addition to this, rise in healthcare spending & surge in vaccination activities will spur respiratory virus infection drugs industry growth. With AI-based multi-program model enabling production of antibiotic resistance drug molecules for various kinds of harmful viruses, the market for respiratory virus infection drugs is anticipated to gain traction in the years ahead. Giant pharma firms are trying to enter into partnerships with other local or regional pharma firms for developing new drugs for treating respiratory virus infections in children, thereby helping respiratory virus infection drugs market explore new areas of growth in ensuing years. Nonetheless, easy access to generic drug substitutes can pose a threat to growth of respiratory virus infection drugs market in near future.

Regional Landscape

North American Market To Hit New Terrains of Growth By 2028

Expansion of respiratory virus infection drugs market during 2021-2028 can be attributed to new drug approvals by regulatory authorities such as U.S. FDA. Apart from this, presence of enhanced healthcare amenities along with early acceptance of advanced therapeutics in healthcare sector in countries like Canada and the U.S. will help respiratory virus infection drugs market in North America gain acceleration. Apart from this, growing healthcare awareness among the people and easy access to diagnostic tests in sub-continent will further contribute towards growth of respiratory virus infection drugs market in North America during 2021-2028.

Competitive Landscape

Key players leveraging industry landscape and profiled in report include AstraZeneca, AbbVie, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Roche Diagnostics Limited, Orion Corporation, Cipla, Inc., Sanofi, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, and Merck & Co., Inc.

The global Respiratory Virus Infection Drugs Market is segmented as follows:

By Drug Type

  • Antibiotics
  • Nasal Decongestants
  • Non-Steroidal Anti-Inflammatory Drugs
  • Cough Suppressants

By Infection Type

  • Respiratory Syncytial Virus Infection 
  • Influenza Virus Infection
  • Para influenza Virus Infection
  • Rhinovirus Infection
  • Adenovirus Infection

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Clinics 

By Route of Administration

  • Oral
  • Parenteral

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Type
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
    • 2.2. Respiratory Virus Infection Drugs Market: Snapshot
  • Chapter 3. Global Respiratory Virus Infection Drugs Market– Industry Analysis
    • 3.1. Respiratory Virus Infection Drugs Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Large-scale utilization of AI and machine learning in drug discovery activities is set to leverage respiratory virus infection drugs market expansion over 2021-2028.
      • 3.2.2. Escalated use of combined drug treatment is slated to boost success rate of treating respiratory virus infection through anti-viral agents such as anti-viral medicines. This, in turn, will promulgate elevation of respiratory virus infection drugs market size within next couple of years.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Drug Type
      • 3.4.2. Market attractiveness analysis By Infection Type
      • 3.4.3. Market attractiveness analysis By Route of Administration
      • 3.4.4. Market attractiveness analysis By Distribution Channel
  • Chapter 4. Global Respiratory Virus Infection Drugs Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Respiratory Virus Infection Drugs Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Respiratory Virus Infection Drugs Market– Drug Type Analysis
    • 5.1. Global Respiratory Virus Infection Drugs Market overview: By Drug Type
      • 5.1.1. Global Respiratory Virus Infection Drugs Market share, By Drug Type, 2020 and 2028
    • 5.2. Antibiotics
      • 5.2.1. Global Respiratory Virus Infection Drugs Market by Antibiotics, 2018–2028(USD Billion)
    • 5.3. Nasal Decongestants
      • 5.3.1. Global Respiratory Virus Infection Drugs Market by Nasal Decongestants, 2018–2028(USD Billion)
    • 5.4. Non-Steroidal Anti-Inflammatory Drugs
      • 5.4.1. Global Respiratory Virus Infection Drugs Market by Non-Steroidal Anti-Inflammatory Drugs, 2018–2028(USD Billion)
    • 5.5. Cough Suppressants
      • 5.5.1. Global Respiratory Virus Infection Drugs Market by Cough Suppressants, 2018–2028(USD Billion)
  • Chapter 6. Global Respiratory Virus Infection Drugs Market– Infection Type Analysis
    • 6.1. Global Respiratory Virus Infection Drugs Market overview: By Infection Type
      • 6.1.1. Global Respiratory Virus Infection Drugs Market share, By Infection Type, 2020 and 2028
    • 6.2. Respiratory Syncytial Virus Infection
      • 6.2.1. Global Respiratory Virus Infection Drugs Market by Respiratory Syncytial Virus Infection , 2018–2028(USD Billion)
    • 6.3. Influenza Virus Infection
      • 6.3.1. Global Respiratory Virus Infection Drugs Market by Influenza Virus Infection, 2018–2028(USD Billion)
    • 6.4. Para Influenza Virus Infection
      • 6.4.1. Global Respiratory Virus Infection Drugs Market by Para Influenza Virus Infection, 2018–2028(USD Billion)
    • 6.5. Rhinovirus Infection
      • 6.5.1. Global Respiratory Virus Infection Drugs Market by Rhinovirus Infection, 2018–2028(USD Billion)
    • 6.6. Adenovirus Infection
      • 6.6.1. Global Respiratory Virus Infection Drugs Market by Adenovirus Infection, 2018–2028(USD Billion)
  • Chapter 7. Global Respiratory Virus Infection Drugs Market– Route of Administration Analysis
    • 7.1. Global Respiratory Virus Infection Drugs Market overview: By Route of Administration
      • 7.1.1. Global Respiratory Virus Infection Drugs Market share, By Route of Administration, 2020 and 2028
    • 7.2. Oral
      • 7.2.1. Global Respiratory Virus Infection Drugs Market by Oral , 2018–2028(USD Billion)
    • 7.3. Parenteral
      • 7.3.1. Global Respiratory Virus Infection Drugs Market by Parenteral, 2018–2028(USD Billion)
  • Chapter 8. Global Respiratory Virus Infection Drugs Market overview: By Distribution Channel
    • 8.1.1. Global Respiratory Virus Infection Drugs Market share, By Distribution Channel, 2020 and 2028
    • 8.2. Hospital Pharmacies
      • 8.2.1. Global Respiratory Virus Infection Drugs Market by Hospital Pharmacies , 2018–2028(USD Billion)
    • 8.3. Drug Stores
      • 8.3.1. Global Respiratory Virus Infection Drugs Market by Drug Stores, 2018–2028(USD Billion)
    • 8.4. Retail Pharmacies
      • 8.4.1. Global Respiratory Virus Infection Drugs Market by Retail Pharmacies, 2018–2028(USD Billion)
    • 8.5. Clinics
      • 8.5.1. Global Respiratory Virus Infection Drugs Market by Clinics, 2018–2028(USD Billion)
  • Chapter 9. Company Profiles
    • 9.1. AstraZeneca
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. AbbVie
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. GlaxoSmithKline plc
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Development
    • 9.4. CHIESI Farmaceutici S.p.A.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Development
    • 9.5. Roche Diagnostics Limited
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. Orion Corporation
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development
    • 9.7. Cipla, Inc.
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Development
    • 9.8. Sanofi
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Development
    • 9.9. Merck & Co., Inc.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Development
    • 9.10. Boehringer Ingelheim International GmbH
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product Portfolio
      • 9.10.4. Business Strategy
      • 9.10.5. Recent Development
    • 9.11. Teva Pharmaceutical Industries Limited
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Product Portfolio
      • 9.11.4. Business Strategy
      • 9.11.5. Recent Development

List of Figures

1. Market research Type
2. Market research methodology
3. Global Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
4. Porter’s Five Forces Analysis
5. Global Respiratory Virus Infection Drugs Marketattractiveness, By Drug Type
6. Global Respiratory Virus Infection Drugs Marketattractiveness, By Route of Administration
7. Global Respiratory Virus Infection Drugs Marketattractiveness, By Infection Type
8. Global Respiratory Virus Infection Drugs Marketattractiveness, By Distribution Channel
9. Global Respiratory Virus Infection Drugs Marketshare by Drug Type ,2020 and 2028 (USD Billion)
10. Global Respiratory Virus Infection Drugs Marketby Antibiotics, 2018–2028(USD Billion)
11. Global Respiratory Virus Infection Drugs Marketby Nasal Decongestants, 2018–2028(USD Billion)
12. Global Respiratory Virus Infection Drugs Marketby Non-Steroidal Anti-Inflammatory Drugs, 2018–2028(USD Billion)
13. Global Respiratory Virus Infection Drugs Marketby Cough Suppressants, 2018–2028(USD Billion)
14. Global Respiratory Virus Infection Drugs Marketshare by Infection Type ,2020 and 2028 (USD Billion)
15. Global Respiratory Virus Infection Drugs Marketby Respiratory Syncytial Virus Infection  , 2018–2028(USD Billion)
16. Global Respiratory Virus Infection Drugs Marketby Influenza Virus Infection, 2018–2028(USD Billion)
17. Global Respiratory Virus Infection Drugs Marketby Para Influenza Virus Infection, 2018–2028(USD Billion)
18. Global Respiratory Virus Infection Drugs Marketby Rhinovirus Infection, 2018–2028(USD Billion)
19. Global Respiratory Virus Infection Drugs Marketby Adenovirus Infection, 2018–2028(USD Billion)
20. Global Respiratory Virus Infection Drugs Marketshare by Route of Administration ,2020 and 2028 (USD Billion)
21. Global Respiratory Virus Infection Drugs Marketby Oral,  2018–2028(USD Billion)
22. Global Respiratory Virus Infection Drugs Marketby Parenteral, 2018–2028(USD Billion)
23. Global Respiratory Virus Infection Drugs Marketshare by Distribution Channel ,2020 and 2028 (USD Billion)
24. Global Respiratory Virus Infection Drugs Marketby Hospital Pharmacies,  2018–2028(USD Billion)
25. Global Respiratory Virus Infection Drugs Marketby Retail Pharmacies, 2018–2028(USD Billion)
26. Global Respiratory Virus Infection Drugs Marketby Clinics, 2018–2028(USD Billion)
27. Global Respiratory Virus Infection Drugs Marketby Drug Stores, 2018–2028(USD Billion)
28. Global Respiratory Virus Infection Drugs Marketshare, by Region, 2020 and 2028
29. North America Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
30. Europe Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
31. Asia Pacific Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
32. Latin America Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
33. The Middle East and Africa Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)


List of Tables

1. Global Respiratory Virus Infection Drugs Market: snapshot
2. Drivers of the Respiratory Virus Infection Drugs Market: impact analysis
3. North America Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
4. North America Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
5. North America Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
6. North America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
7. The U.S. Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
8. The U.S. Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
9. The U.S. Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
10. The U.S. Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
11. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
12. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
13. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
14. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
15. Europe Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
16. Europe Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
17. Europe Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
18. Europe Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
19. UK Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
20. UK Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
21. UK Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
22. UK Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
23. France Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
24. France Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
25. France Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
26. France Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
27. Germany Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
28. Germany Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
29. Germany Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
30. Germany Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
31. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
32. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
33. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
34. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
35. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
36. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
37. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
38. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
39. China Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
40. China Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
41. China Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
42. China Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
43. Japan Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
44. Japan Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
45. Japan Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
46. Japan Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
47. India Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
48. India Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
49. India Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
50. India Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
51. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
52. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
53. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
54. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
55. Latin America Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
56. Latin America Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
57. Latin America Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
58. Latin America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
59. Brazil Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
60. Brazil Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
61. Brazil Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
62. Brazil Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
63. Rest of Latin America Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
64. Rest of Latin  America Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
65. Rest of Latin America Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
66. Rest of Latin  America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
67. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
68. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
69. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
70. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
71. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
72. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
73. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
74. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
75. South Africa Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
76. South Africa Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
77. South Africa Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
78. South Africa Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
79. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
80. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
81. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
82. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
 
 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Massive use of artificial intelligence and machine learning in drug discovery is projected to favorably influence growth of respiratory virus infection drugs market. Humungous use of combination therapy is projected to boost rate of success of treating respiratory virus infection through anti-viral drugs. This, in turn, will facilitate elevation of respiratory virus infection drugs market size in upcoming years. Apart from this, effective drug delivery through nanotechnology is projected to provide new growth prospects for respiratory virus infection drugs market in near future. In addition to this, rise in healthcare spending & surge in vaccination activities will spur respiratory virus infection drugs industry growth. With AI-based multi-program model enabling production of antibiotic resistance drug molecules for various kinds of harmful viruses, the market for respiratory virus infection drugs is anticipated to gain traction in the years ahead. Giant pharma firms are trying to enter into partnerships with other local or regional pharma firms for developing new drugs for treating respiratory virus infections in children, thereby helping respiratory virus infection drugs market explore new areas of growth in ensuing years.   

 

According to Zion market research report, the global Respiratory Virus Infection Drugs market accrued earnings worth approximately 40.12 (USD Billion) in 2020 and is predicted to gain revenue of about 57.23(USD Billion) by 2028, is set to record a CAGR of nearly 7.5% over the period from 2021 to 2028.

North America will contribute lucratively towards the global market value over the estimated timeline. The regional market surge is subject to new drug approvals by regulatory authorities such as U.S. FDA. Apart from this, presence of enhanced healthcare amenities along with early acceptance of advanced therapeutics in healthcare sector in countries like Canada and the U.S. will help respiratory virus infection drugs market in North America gain acceleration. Apart from this, growing healthcare awareness among the people and easy access to diagnostic tests in sub-continent will further contribute towards growth of respiratory virus infection drugs market in North America during 2021-2028.    

The key market participants include AstraZeneca, AbbVie, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Roche Diagnostics Limited, Orion Corporation, Cipla, Inc., Sanofi, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, and Merck & Co., Inc.

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social